Clopidogrel (Plavix)

A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.

Also Known As:

Plavix; Clopidogrel Besilate; Clopidogrel Besylate; Clopidogrel Bisulfate; Clopidogrel Hydrochloride; Clopidogrel Napadisilate; Clopidogrel Sandoz; Clopidogrel, (+)(S)-isomer; Clopidogrel-Mepha; Iscover; PCR 4099; PCR-4099; SC 25989C; SC 25990C; SR 25989; Clopidogrel Mepha; Methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)acetate

Networked: 7591 relevant articles (744 outcomes, 1982 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Angiolillo, Dominick J: 140 articles (06/2022 - 04/2004)
2.	Bhatt, Deepak L: 128 articles (01/2022 - 01/2002)
3.	Cannon, Christopher P: 100 articles (08/2021 - 10/2002)
4.	Gurbel, Paul A: 85 articles (06/2021 - 02/2003)
5.	Storey, Robert F: 76 articles (04/2022 - 09/2002)
6.	Wallentin, Lars: 74 articles (04/2022 - 05/2003)
7.	Montalescot, Gilles: 68 articles (09/2021 - 01/2004)
8.	Harrington, Robert A: 65 articles (01/2022 - 09/2004)
9.	Tantry, Udaya S: 64 articles (06/2021 - 01/2005)
10.	Mahaffey, Kenneth W: 62 articles (01/2022 - 05/2008)

Related Diseases

1.	Acute Coronary Syndrome 01/01/2006 - "Clopidogrel given for up to 1 year in patients undergoing PCI after presentation with acute coronary syndromes is a highly cost-effective treatment strategy." 04/01/2012 - "Based on their beneficial results in comparison to clopidogrel, these agents have found their way into the recent international guidelines for treatment of patients with acute coronary syndromes. " 01/01/2007 - "The efficacy of clopidogrel, as an established anti-platelet agent for the acute coronary syndrome treatment and for the thrombotic complications prevention after percutaneous coronary angioplasty and coronary artery stenting has been supported by the evidence of several major randomized clinical trials. " 12/01/2016 - "It is more effective than clopidogrel in preventing thrombotic events in acute coronary syndrome patients. " 07/01/2010 - "Higher clopidogrel doses have been associated with improved clinical outcomes, especially in those presenting with acute coronary syndrome. "
2.	Hemorrhage 01/01/2023 - "However, clopidogrel had the highest probability of being most effective for major bleeding and all-cause mortality. " 04/01/2010 - "However, recent studies have suggested that there is large inter-individual response variability to these drugs (especially to clopidogrel) and that improved inhibition of platelet reactivity using higher doses or new, more potent agents would further reduce the occurrence of cardiovascular events, but may also increase the risk of bleeding. " 01/01/2015 - "These agents have a faster-acting, more-potent, and more-predictable antiplatelet effect than clopidogrel, which translates into improved clinical outcomes in patients with ACS, albeit at the expense of an increased risk of bleeding. " 10/01/2013 - "Platelet function testing may have a role in monitoring therapeutic efficacy when clopidogrel is the chosen agent and in safety when more potent drugs are used, especially in patients with high bleeding risk. " 02/01/2012 - "Recently completed studies suggest that in patients with ACS undergoing PCI, higher-than-standard clopidogrel dosing regimens provide greater inhibition of platelet function and improved clinical outcomes with a small but significant increase in major bleeding. "
3.	Stroke (Strokes) 09/14/2005 - "Overall, pretreatment with clopidogrel resulted in a highly significant reduction in cardiovascular death, MI, or stroke from randomization through 30 days (70 [7.5%] vs 112 [12.0%]; adjusted OR, 0.59 [95% CI, 0.43-0.81]; P = .001; number needed to treat = 23). " 02/01/2011 - "Clopidogrel use was associated with a non-significant reduction of perioperative stroke/death (4.3% vs. 2.4%; p = 0.13) and disabling stroke (1.2% vs. 1.0%; p = 1) rates. " 07/01/2006 - "Clopidogrel has not shown significant reduction in reoccurrence of stroke and has not been studied for patients with a previous TIA. " 01/01/2009 - "Furthermore, results from the recent PROFESS trial suggest that ASA-ERDP and clopidogrel are equally effective in reducing the risk of recurrent stroke, though further studies are needed to compare the efficacy and safety of these two agents. " 03/01/2012 - "Thus, for a patient harboring a mutated allele, clopidogrel does not provide effective protection against stroke. "
4.	Myocardial Infarction 01/01/2020 - "A significant reduction in risks of all-cause death and myocardial infarction was also observed with the use of potent oral P2Y12 inhibitors compared with clopidogrel. " 07/04/2006 - "Clopidogrel was also associated with a significant reduction in the odds of an in-hospital death or myocardial infarction in patients who achieved partial (OR 0.30, p = 0.003) or complete STRes at 90 min (OR 0.49, p = 0.056), whereas clinical benefit was not apparent in patients who had no STRes (OR 0.98, p = 0.95) (p for interaction = 0.027). " 04/01/2012 - "The higher maintenance dose of clopidogrel was associated with a significant reduction in cardiovascular (CV) death and myocardial infarction (MI) (0% vs. 11·4%, P = 0·04) and in CV death, MI or target vessel revascularization (24·6% vs. 3·1%; P = 0·01) during 1 year. " 01/01/2011 - "Recent studies have raised concerns that interaction of PPIs and clopidogrel could reduce the efficacy of clopidogrel and thus increase events such as myocardial infarction. " 01/01/2006 - "Efficacy of clopidogrel in acute myocardial infarction (AMI) was studied only in two trials. "
5.	Thrombosis (Thrombus) 04/01/2005 - "Because of its central role in the formation and stabilization of a thrombus, the P2Y (12) receptor is a well-established target of antithrombotic drugs such as clopidogrel, which has proven efficacy in many clinical trials and experimental models of thrombosis. " 01/01/2021 - "Finally, in the present canine patient with arterial thrombosis, thrombolysis with rtPA successfully improved clinical symptoms and the following administration of clopidogrel inhibited the formation of additional thrombus." 01/01/2017 - "Ex vivo addition of PC or vWF does not overcome the effects of clopidogrel in this model, but the combination of both shows a mild and significant improvement in thrombus size." 10/01/2016 - "Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis." 08/15/2009 - "The results of the VASP-P assay did not correlate with the presence of ST. In conclusion, patients who experienced DES thrombosis demonstrated significantly greater rates of clopidogrel resistance as determined by P2Y12 reaction units, but not VASP-P, compared with patients without DES thrombosis. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	Ticagrelor
3.	Prasugrel Hydrochloride
4.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
5.	Ticlopidine (Ticlid)
6.	Dipyridamole (Persantine)
7.	Cytochrome P-450 CYP2C19
8.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
9.	Warfarin (Coumadin)
10.	Cilostazol (Pletal)

Related Therapies and Procedures

1.	Therapeutics
2.	Percutaneous Coronary Intervention
3.	Stents
4.	Secondary Prevention
5.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)